This unit of study is designed to introduce students with a basic understanding of pharmacology to the field of medicinal chemistry associated with drug design and development. The course covers the fundamental aspects of drug discovery and development with reference to the essentials of chemistry and illustrates drug development with examples that include neuraminidase inhibitors and angiotensin converting enzyme inhibitors. The role of computers in drug design is emphasised by classwork and assignments on molecular modelling and structure-activity relationships. The course also extends to a section on the design of diverse pharmacological agents which include compounds for imaging by positron emission tomography (PET), and kinase inhibitors.
Unit details and rules
Academic unit | |
---|---|
Credit points | 6 |
Prerequisites
?
|
(PCOL2011 or PCOL2021 or MEDS2002) or [BMED2401 and 6cp from (BMED2402 or BMED2405)] or 12cp from BCMB2XXX |
Corequisites
?
|
None |
Prohibitions
?
|
PCOL3912 |
Assumed knowledge
?
|
None |
Available to study abroad and exchange students | Yes |
Teaching staff
Coordinator | Brent McParland, brent.mcparland@sydney.edu.au |
---|---|
Lecturer(s) | Margaret Sunde, margaret.sunde@sydney.edu.au |
Robert Vandenberg, robert.vandenberg@sydney.edu.au | |
Josep Font, josep.font@sydney.edu.au | |
Rachel Codd, rachel.codd@sydney.edu.au | |
Michael Kassiou, michael.kassiou@sydney.edu.au |